Arli Aditya Parikesit

Indonesia International Institute for Life Sciences

Arli Aditya Parikesit is the Vice-Rector of Research and Innovation at the Indonesia International Institute for Life Sciences (I3L). He received his bachelor’s and master’s degrees in chemistry from the Faculty of Mathematics and Natural Sciences, University of Indonesia. His doctoral research at the Bioinformatics Group, Faculty of Informatics and Mathematics, University of Leipzig, Germany is focused on the utilization of modern protein domain annotation techniques for the three domains of life. Dr. Arli is also an expert on immunoinformatics, bioinformatics algorithms, structural bioinformatics, in-silico drug design, and in-silico transcriptomics. Currently, Dr. Arli is applying his expertise to the development of a COVID-19 drug and vaccine design pipeline.

3books edited

4chapters authored

Latest work with IntechOpen by Arli Aditya Parikesit

COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences.

Go to the book